These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Topical 0.1% prednisolone lowers nerve growth factor expression in keratoconjunctivitis sicca patients. Lee HK; Ryu IH; Seo KY; Hong S; Kim HC; Kim EK Ophthalmology; 2006 Feb; 113(2):198-205. PubMed ID: 16360211 [TBL] [Abstract][Full Text] [Related]
7. Corneal and conjunctival toxicity with low-dose cytosine arabinoside. Barletta JP; Fanous MM; Margo CE Am J Ophthalmol; 1992 May; 113(5):587-8. PubMed ID: 1575237 [No Abstract] [Full Text] [Related]
8. [Experience in therapy and prophylaxis of epidemic keratoconjunctivitis (author's transl)]. Hiti H; Hanselmayer H; Hofmann H Klin Monbl Augenheilkd; 1979 Mar; 174(3):456-61. PubMed ID: 480819 [TBL] [Abstract][Full Text] [Related]
9. [Effects of the rational use of corticosteroids eye drops for the prevention of ocular toxicity in high-dose cytosine arabinoside therapy]. Itoh M; Aoyama T; Yamamura Y; Nakajima K; Nakamura K; Kotaki H; Matsuyama T; Saitoh T; Kami M; Chiba S; Hirai H; Yazaki Y; Iga T Yakugaku Zasshi; 1999 Mar; 119(3):229-35. PubMed ID: 10198598 [TBL] [Abstract][Full Text] [Related]
10. Reduced efficacy of topical corticosteroid in preventing cytarabine-induced kerato-conjunctivitis in patients receiving high-dose cytarabine and total body irradiation for allogeneic hematopoietic stem cell transplantation. Mori T; Watanabe M; Kurotori-Sotome T; Ito C; Yamada K; Yashima T; Kobayashi N; Kondo S; Aisa Y; Kato J; Ogawa Y; Tsubota K; Shigematsu N; Kubo A; Ikeda Y; Okamoto S Bone Marrow Transplant; 2008 Aug; 42(3):197-9. PubMed ID: 18500372 [TBL] [Abstract][Full Text] [Related]
12. An in vitro method which assesses corneal epithelial toxicity due to antineoplastic, preservative and antimicrobial agents. Lazarus HM; Imperia PS; Botti RE; Mack RJ; Lass JH Lens Eye Toxic Res; 1989; 6(1-2):59-85. PubMed ID: 2488034 [TBL] [Abstract][Full Text] [Related]
13. Anterior uveitis as a complication of treatment with high dose cytosine-arabinoside. Planer D; Cukierman T; Liebster D; Ilsar M; Chajek-Shaul T Am J Hematol; 2004 Jul; 76(3):304-6. PubMed ID: 15224375 [TBL] [Abstract][Full Text] [Related]
14. Topical prophylaxis of conjunctivitis induced by high-dose cytosine arabinoside. Matteucci P; Carlo-Stella C; Di Nicola M; Magni M; Guidetti A; Marchesi M; Gianni AM Haematologica; 2006 Feb; 91(2):255-7. PubMed ID: 16461314 [TBL] [Abstract][Full Text] [Related]
15. The use of high-dose cytosine arabinoside for non-Hodgkin's lymphoma. Richards MA; Barnett MJ; Waxman JH; Rohatiner AZ; Dhaliwal HS; Gallagher CJ; Lister TA Semin Oncol; 1985 Jun; 12(2 Suppl 3):223-6. PubMed ID: 4012341 [No Abstract] [Full Text] [Related]
16. Comparison of Topical Application of TSG-6, Cyclosporine, and Prednisolone for Treating Dry Eye. Kim YJ; Ryu JS; Park SY; Lee HJ; Ko JH; Kim MK; Wee WR; Oh JY Cornea; 2016 Apr; 35(4):536-42. PubMed ID: 26807900 [TBL] [Abstract][Full Text] [Related]
17. [Cyclosporine eye drops: A 4-year retrospective study (2009-2013)]. Kauss Hornecker M; Charles Weber S; Brandely Piat ML; Darrodes M; Jomaa K; Chast F J Fr Ophtalmol; 2015 Oct; 38(8):700-8. PubMed ID: 26371985 [TBL] [Abstract][Full Text] [Related]
18. [Selective treatment of leukemia L1210 with combination of deoxycytidine and lethal doses of cytosine arabinoside]. Bukhman VM; Lichinitser MR; Svet-Moldavskiĭ GIa; Mkheidze DM Biull Eksp Biol Med; 1978 Mar; 85(3):340-3. PubMed ID: 276385 [TBL] [Abstract][Full Text] [Related]